ArticleInternational journal of nephrology and renovascular disease2021
Temporal Clustering of Antiglomerular Basement Membrane Disease in COVID-19 Pandemic: A Case Series.
Article in International journal of nephrology and renovascular disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Ascertaining the mechanistic etiology of COVID-associated glomerulonephritis: a systematic review.Frontiers in medicine · 2025Pooled it
- A case report of concomitant anti-glomerular basement membrane disease, IgA nephropathy, and membranous nephropathy.BMC nephrology · 2026Article
- Inflammatory tropism in COVID-19: a comparative analysis of Delta and Omicron variants.BMC immunology · 2025Article
- Case Report: Anti-glomerular basement membrane disease following COVID-19 infection.Frontiers in nephrology · 2025Article
- Autoimmunity and Infection in Glomerular Disease.Microorganisms · 2023Review
- Anti-glomerular basement membrane glomerulonephritis following COVID-19 infection without clinically evident pneumonia.International urology and nephrology · 2023Article
- COVID-19 and Glomerular Diseases.Kidney international reports · 2023Review
- Double-Positive Anti-Glomerular Basement Membrane Antibody and Myeloperoxidase Antineutrophil Cytoplasmic Autoantibody-Associated Glomerulonephritis Post COVID-19 mRNA vaccine: A Case Series of 4 Patients.Canadian journal of kidney health and disease · 2023Article
- Epidemiology, Impact, and Management Strategies of Anti-Glomerular Basement Membrane Disease.International journal of nephrology and renovascular disease · 2022Review
- Anti-glomerular basement membrane disease in children: can Sars-Cov-2 be a trigger?Jornal brasileiro de nefrologiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-glomerular basement membrane disease (anti-GBM) affects mainly kidneys and lungs. It requires aggressive immunosuppressive treatment. Since the emergence of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), there has been an increased number of new cases of anti-GBM disease presenting as rapidly progressive glomerulonephritis (RPGN). The causal relationship is still speculative. We report a case series of four patients affected with COVID-19 infection presenting later with anti-GBM disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.